Tools
Stock profile

Adaptive Biotechnologies Corp (ADPT)

ADPT · Latest close $28.46 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$28.46
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
1
vs previous quarter

Adaptive Biotechnologies Corp (ADPT) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $14.7M sold). Latest close $28.46 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-14.7M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Viking Global Investors · Perceptive Advisors · Polen Capital Management — 3 tracked funds hold ADPT. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 65 sales ($14.7M). Insider trading

Often held alongside

Roivant Sciences Ltd. (ROIV) · Natera, Inc. (NTRA) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Viking Global Investors1.83%29,993,708HELD Q3 filed Nov 16
Perceptive Advisors0.39%1,217,325ADDED (+698.2%) Q3 filed Nov 16
Polen Capital Management0.02%102,457TRIMMED (-11.7%) Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +27.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

30.263.332024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding298 of 8,857 filers
Long-only filers among them297
Change vs 2026 Q1+11 net · 282 entered · 271 exited
Shares reported, all filers155,305,725
Reported value, all filers$3.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$277.0M
Net income · FY2025$-59.5M
Total assets · FY2025$512.7M
Shares outstanding159,595,842
Market cap (at latest close)$4.5B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 202611,991,988
Share of shares outstanding7.51%
Days to cover5.03

Shares short at recent settlements — Jul 31, 2026: 12.5M · Aug 14, 2026: 13.3M · Aug 31, 2026: 11.7M · Sep 15, 2026: 13.5M · Sep 30, 2026: 11.8M · Oct 15, 2026: 12.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 3K · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 65 sales by 4 insiders ($14.7M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 13, 2026RUBINSTEIN JULIEPresident and COOSell11,466$28.93$331.7KSEC filing
Nov 12, 2026RUBINSTEIN JULIEPresident and COOSell11,881$29.40$349.3KSEC filing
Nov 11, 2026BOBULSKY SUSANChief Commercial Officer, MRDSell1,875$32.00$60.0KSEC filing
Nov 11, 2026RUBINSTEIN JULIEPresident and COOSell4,983$30.29$150.9KSEC filing
Nov 11, 2026RUBINSTEIN JULIEPresident and COOSell6,898$31.22$215.4KSEC filing
Nov 10, 2026RUBINSTEIN JULIEPresident and COOSell9,981$29.35$292.9KSEC filing
Nov 10, 2026RUBINSTEIN JULIEPresident and COOSell1,900$30.41$57.8KSEC filing
Nov 9, 2026RUBINSTEIN JULIEPresident and COOSell1,100$28.87$31.8KSEC filing
Nov 9, 2026RUBINSTEIN JULIEPresident and COOSell8,381$30.15$252.7KSEC filing
Nov 9, 2026RUBINSTEIN JULIEPresident and COOSell2,400$30.58$73.4KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 6, 2026SUSAN BOBULSKYOfficer6,444$192.3KOct 6, 2026SEC filing
Oct 1, 2026JULIE RUBINSTEINOfficer379,777$11.0MOct 1, 2026SEC filing
Sep 16, 2026FRANCIS LOOfficer142,198$3.8MSep 16, 2026SEC filing
Sep 15, 2026SUSAN BOBULSKYOfficer1,195$29.6KSep 15, 2026SEC filing
Aug 26, 2026KATHERINE E OWENDirector9,615$250.0KAug 26, 2026SEC filing
Aug 20, 2026Harlan RobinsFormer Officer402,160$10.2MAug 20, 2026SEC filing
Aug 19, 2026Harlan RobinsFormer Officer215,632$5.5MAug 19, 2026SEC filing
Aug 18, 2026Chad RobinsOfficer278,676$6.8MAug 18, 2026SEC filing
Aug 18, 2026Harlan RobinsFormer Officer261,044$6.4MAug 18, 2026SEC filing
Aug 18, 2026ROBERT M HERSHBERGDirector30,664$748.3KAug 18, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 15, 2026VIKING GLOBAL INVESTORS LPSC 13G/A29,993,70818.8%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A11,992,4487.9%Dec 31, 2025SEC filing
Jul 9, 2025Rubric Capital Management LPSC 13G/A6,256,8474.1%Jun 30, 2025SEC filing
Jun 6, 2025ARK Investment Management LLCSC 13G/A4,398,6692.9%May 31, 2025SEC filing
May 14, 2025ARK Investment Management LLCSC 13G7,732,5705.2%Mar 31, 2025SEC filing
May 7, 2025ARK Investment Management LLCSC 13G/A6,067,8094.0%Apr 30, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A9,940,8466.7%Mar 31, 2025SEC filing
Feb 14, 2025ARK Investment Management LLCSC 13G/A9,424,0746.4%Dec 31, 2024SEC filing
Feb 13, 2025Nikko Asset Management Americas, Inc.SC 13G/A6,833,1374.6%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 35 Lobbying Disclosure Act filings named this company as client, 2015–2024; most common issues: Health Issues (28), Medicare/Medicaid (25), Medical/Disease Research/Clinical Labs (8).

Federal contracts: $2.1M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$184.0K
FY2022$422.1K
FY2023$665.2K
FY2024$611.9K
FY2025$-32.6K
FY2026$205.5K

Largest awards collected

Award IDAgencyAmountStart
HT001419C0006Department of Defense$385.9KAug 29, 2019
75N93023P00060Department of Health and Human Services$308.4KNov 10, 2022
36C25026P0251Department of Veterans Affairs$243.8KDec 29, 2025
75N90024P00658Department of Health and Human Services$234.9KMar 17, 2021
W81K0025CA004Department of Defense$142.3KMar 14, 2025

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Distress Risk (Altman Z″) — Z″-Score: -5.93 · Working capital / assets: 0.41 · Retained earnings / assets: -2.66 · EBIT / assets: -0.11 · Equity / liabilities: 0.76

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold ADPT — ranked by lift, the co-holding pattern described in Methodology: Roivant Sciences Ltd. (ROIV) · Natera, Inc. (NTRA) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN).

6 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 29, 20262.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and ExhibitsSEC filing
Jun 22, 20261.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 3.02 Unregistered Sales of Equity Securities · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Roivant Sciences Ltd. (ROIV) · Track Record: how the signals scored · Practice timing on ADPT

One email a week: the week’s new filings and research. Subscribe free

← ADP  ·  ADSK →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.